Holen Sie sich die Stockscreener-App
8.33
2.84%
0.23
Handel nachbörslich:
8.34
0.010
+0.12%
Schlusskurs vom Vortag:
$8.10
Offen:
$8.23
24-Stunden-Volumen:
3.47M
Relative Volume:
0.58
Marktkapitalisierung:
$1.81B
Einnahmen:
$51.95M
Nettoeinkommen (Verlust:
$-265.94M
KGV:
-5.7912
EPS:
-1.4384
Netto-Cashflow:
$-216.89M
1W Leistung:
-1.88%
1M Leistung:
-12.32%
6M Leistung:
-31.94%
1J Leistung:
+10.62%
1-Tages-Spanne:
$8.18
$8.445
1-Wochen-Bereich:
$7.785
$8.54
52-Wochen-Spanne:
$5.80
$16.44
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Firmenname
Ocular Therapeutix Inc
Sektor
Branche
Telefon
781-357-4000
Adresse
15 CROSBY DRIVE, BEDFORD, MA
Compare OCUL vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
8.33 | 1.76B | 51.95M | -265.94M | -216.89M | -1.4384 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-15 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-04-08 | Eingeleitet | William Blair | Outperform |
| 2025-03-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-03-11 | Eingeleitet | Needham | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-20 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-05-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2024-02-09 | Eingeleitet | BofA Securities | Buy |
| 2023-04-21 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-08-10 | Fortgesetzt | Berenberg | Buy |
| 2021-08-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-11-13 | Bestätigt | Raymond James | Strong Buy |
| 2020-08-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-03 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | Herabstufung | Cowen | Outperform → Market Perform |
| 2019-05-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-21 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-11-15 | Eingeleitet | Raymond James | Strong Buy |
| 2018-09-07 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-10-24 | Eingeleitet | Guggenheim | Buy |
| 2017-07-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-07-12 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-06-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-11-15 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-08-11 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-02-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Ocular Therapeutix Inc Aktie (OCUL) Neueste Nachrichten
Ocular Therapeutix at RBC Conference: Promising AXPAXLI Data By Investing.com - Investing.com Canada
OCUL: AXPAXLI showed phase III superiority over anti-VEGF, with strong regulatory and clinical momentum - TradingView
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Citizens reiterates Ocular Therapeutix stock rating amid litigation By Investing.com - Investing.com Canada
Jeffrey S. Heier, MD, Chief Scientific Officer, Ocular Therapeutix - Healio
OCUL Stock Price, Quote & Chart | OCULAR THERAPEUTIX INC (NASDAQ:OCUL) - ChartMill
EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug - Reuters
EyePoint sues Ocular over claims related to lead asset - MSN
EyePoint (EYPT) Sues Ocular Therapeutix (OCUL) Over False Claims - GuruFocus
EyePoint files a lawsuit against Ocular (EYPT:NASDAQ) - Seeking Alpha
EyePoint, Inc. Files Complaint Against Ocular Therapeutix—Key Details from Latest 8-K SEC Filing - Minichart
On March 20, 2026, EyePoint has officially filed a lawsuit against biotechnology company Ocular Therapeutix in the Superior Court of Middlesex County, Massachusetts, USA. - Bitget
EyePoint Sues Ocular Therapeutix Over Alleged Defamation - TipRanks
Cantor Fitzgerald L. P. Buys Shares of 201,865 Ocular Therapeutix, Inc. $OCUL - MarketBeat
Ocular Therapeutix (OCUL) Is Down 6.8% After VR Adviser Trims Stake Amid Margin Pressure - Sahm
VR Adviser Reduces Ocular Therapeutix Stake in Q4 2025 | Portfolio ImpactNews and Statistics - IndexBox
What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down - AOL.com
Ocular Therapeutix, Inc. (OCUL): A bull case theory - MSN
OCULAR THERAPEUTIX, INC. (OCUL) - MSN
Is It Time To Reassess Ocular Therapeutix (OCUL) After Its Recent Share Price Slide - Yahoo Finance
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Short Interest Up 20.0% in February - MarketBeat
Ocular Therapeutix Stock & Financial Performance Review 2026News and Statistics - IndexBox
3 Reasons to Avoid OCUL and 1 Stock to Buy Instead - Yahoo Finance
A Look At Ocular Therapeutix (OCUL) Valuation After Recent Share Price Weakness - simplywall.st
Ocular Therapeutix Experiences Revision in Stock Evaluation Amid Market Challenges - Markets Mojo
201,865 Shares in Ocular Therapeutix, Inc. $OCUL Bought by Cantor Fitzgerald L. P. - MarketBeat
Is Ocular Therapeutix (OCUL) Pricing Reflect Its Volatile Returns And Rich Sales Multiple? - simplywall.st
Sanofi Rumored Bid And Regulatory Shifts Reframe Ocular Therapeutix Valuation - Sahm
Ocular Therapeutix, Inc. $OCUL Shares Purchased by Avoro Capital Advisors LLC - MarketBeat
Ocular Therapeutix Opens with 8.61% Gain Amid Ongoing Financial Challenges - Markets Mojo
Ocular Therapeutix Gets Black Eye, But I See Stock Rising on New Drug - TheStreet Pro
Rosalind Advisors Inc. Decreases Stock Position in Ocular Therapeutix, Inc. $OCUL - MarketBeat
Pharma Sector Q1 2026 Earnings Review: Mixed Results & Future OutlookNews and Statistics - IndexBox
Pharmaceuticals Stocks Q4 Highlights: Ocular Therapeutix (NASDAQ:OCUL) - Yahoo Finance
Ocular Therapeutix at The Citizens Life Sciences Conference: AXPAXLI’s Promising Results - Investing.com Canada
OCUL: AXPAXLI's phase III success sets a new standard in wet AMD, with regulatory approval in progress - TradingView
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Rhenman & Partners Asset Management AB Buys Shares of 202,000 Ocular Therapeutix, Inc. $OCUL - MarketBeat
Can Ocular Therapeutix Inc. stock surprise with earnings upsideJuly 2025 Intraday Action & Technical Buy Zone Confirmation - Naître et grandir
Ocular Therapeutix Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Why Ocular Therapeutix (OCUL) Is Up 16.2% After Detailing Retinal Pipeline Progress And Upcoming Milestones - Sahm
Ocular Therapeutix, Inc. $OCUL Shares Bought by Vanguard Group Inc. - MarketBeat
New Ocular Therapeutix Price Target as Stock Prepares to Blow Through the Old One - TheStreet Pro
Ocular Therapeutix, Inc. (OCUL) Competitors - Meyka
Ocular Therapeutix (OCUL) Gets a Buy from Piper Sandler - The Globe and Mail
Ocular Therapeutix, Inc. (OCUL) Presents at 49th Annual Meeting of the Macula SocietySlideshow - Seeking Alpha
GE Aerospace To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Ocular Therapeutix, Inc. (OCUL) Stock Analysis: 136% Potential Upside Captivates Investor Interest - DirectorsTalk Interviews
Ocular Therapeutix Stock Jumps 22.8% After Conference Update Ahead of Earnings - TIKR.com
Ocular Therapeutix (OCUL): Analyst Raises Price Target Amid Stea - GuruFocus
Finanzdaten der Ocular Therapeutix Inc-Aktie (OCUL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):